Check for updates

CASE REPORT

Case Report: Levetiracetam causing acute liver failure complicating post-operative management in a neurosurgical patient [version 1; peer review: 2 approved]

Sharanya Jayashankar , Sunil Munakomi , Vignesh Sayeerajan, Prakash Kafle , Pramod Chaudhary, Jagdishchandra Thingujam, Deepak Poudel, Iype Cherian

Department of Neurosurgery, Nobel Medical College and Teaching Hospital, Biratnagar, 0977, Nepal

V1 First published: 15 Feb 2019, 8:187
<https://doi.org/10.12688/f1000research.18198.1>
 Latest published: 15 Feb 2019, 8:187
<https://doi.org/10.12688/f1000research.18198.1>

Abstract

Background: Herein we report a rare case of acute liver failure due to levetiracetam, which has been considered to have an excellent safety profile with minimal hepatic side effects.

Case presentation: A 55-year-old male patient presenting with sudden onset dizziness, slurring of speech and headache was operated for posterior fossa cerebellar hematoma. His post-surgical period was complicated by development of icterus with elevation of liver enzymes. After ruling out common inciting factors, it was decided to stop levetiracetam which was given prophylactically for preventing seizures owing to presence of external ventricular drain. From the next day patient had dramatic improvement in liver functions and sensorium.

Conclusions: We would like to highlight this side effect that is potentially life threatening, though rare, of levetiracetam, which is very commonly used in today's practice and fast superseding all other time-tested antiepileptics.

Keywords

Levetiracetam, anti-epileptics, hepatotoxicity

Open Peer Review

Approval Status

	1	2
version 1		
15 Feb 2019	view	view

1. **Subish Palaian** , Gulf Medical University, Ajman, United Arab Emirates

2. **Pathiyil Ravi Shankar** , Health City University, Gros Islet, Saint Lucia

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Sharanya Jayashankar (drsharanya2006@gmail.com)

Author roles: **Jayashankar S:** Conceptualization, Methodology, Resources, Writing – Original Draft Preparation; **Munakomi S:** Supervision, Writing – Review & Editing; **Sayeerajan V:** Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Kafle P:** Validation, Writing – Review & Editing; **Chaudhary P:** Visualization, Writing – Review & Editing; **Thingujam J:** Validation, Writing – Review & Editing; **Poudel D:** Visualization, Writing – Review & Editing; **Cherian I:** Supervision

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2019 Jayashankar S *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Jayashankar S, Munakomi S, Sayeerajan V *et al.* **Case Report: Levetiracetam causing acute liver failure complicating post-operative management in a neurosurgical patient [version 1; peer review: 2 approved]** F1000Research 2019, 8:187 <https://doi.org/10.12688/f1000research.18198.1>

First published: 15 Feb 2019, 8:187 <https://doi.org/10.12688/f1000research.18198.1>

Introduction

Seizure complicates major subsets of patients with stroke, and newer anti-epileptics are being favored in many clinical settings for seizure prophylaxis due to their good safety profile¹. Levetiracetam has become one of the most commonly used antiepileptic in current practice for treatment as well as prophylaxis against seizures.

Drug-induced liver injury owing to antiepileptic drugs (AED) is well recognized². It has been reported to occur more commonly with phenytoin and carbamazepine, and very rarely with valproate². The consequences of such an injury can be alarming, resulting in harbingering death or the need for liver transplantation. Therefore, newer AED with minimal or no hepatic metabolism are being favored as first line drugs³.

Herein, we report a case of acute liver injury following levetiracetam usage in a post-operative patient of intracerebellar hemorrhage at our Neurosurgery Intensive Care Unit. We implicate a rare but life-threatening effect of a very commonly used anti-epileptic drug. There have been only few case reports of acute liver failure following use of levetiracetam and none were in post-operative neurosurgery cases⁴⁻⁶.

Case report

A 55-year-old male patient from a remote village in Biratnagar presented to our emergency department with complaints of sudden onset dizziness, slurring of speech and headache. He was a known hypertensive but not on regular medication or regular follow-up. Neurological examination revealed Glasgow Coma Scale (GCS) of eye opening 4; Verbal 5; and Motor 5, on admission with his bilateral pupils equal and reactive to light. He had no focal neurological deficits or features of meningeal irritation. An emergent Computerized Tomography scan of the head showed features suggestive of cerebellar bleed with fourth ventricle compression with herniation and ventricular extension. While arranging for cerebral angiography, there was a sudden fall in GCS to E1V1M3, and thereby the patient underwent emergency suboccipital craniectomy with evacuation of cerebellar bleed with placement of external ventricular drain.

The patient's post-operative medications included ceftriaxone (1gram intravenous every 8th hourly), prophylactic levetiracetam (500 milligram intravenous every 12th hourly), Pantoprazole (40 milligram intravenous every 12th hourly), amlodipine (5 milligram via nasogastric tube 12 hourly), Losartan (50 milligram 12 hourly via Nasogastric tube), and Metoprolol (50 milligram via nasogastric tube 12 hourly). His immediate post-operative GCS improved to E3VtM6.

However, on 3rd post-operative day, the GCS fell to E1VtM4. Repeat CT head was uneventful. The patient was noted to have gross icterus and his liver function test revealed total bilirubin of 9.4 mg/dl (normal, 0.1mg/dl), direct 2.0 mg/dl (normal, 0-0.35mg/dl); aspartate aminotransaminase/serum glutamic-oxaloacetic transaminase (AST/SGOT) of 911 IU/L; (normal, 10-40 IU/L); alanine aminotransferase/serum glutamic-pyruvic

transaminase (ALT/SGPT) of 926 IU/L (normal, 10-40 IU/L); alkaline phosphatase (ALP) of 298; (normal, 40-112 U/L); International Normalized ratio (INR) of 1.09 (normal, <1.1). Complete blood counts were done to rule out sepsis and were normal. Ultrasound of the abdomen and peripheral smear (for identifying features of obstructive jaundice as well as portal hypertension and ruling out hemolysis for raised bilirubin respectively) were normal. So, a possibility of drug induced liver injury causing acute hepatic failure was considered. Since none of the drugs prescribed were commonly implicated to have hepatotoxic effects, we considered the possibility of levetiracetam following a thorough literature search and hence stopped the drug. We also prescribed prophylactic hepatic encephalopathy regimen with strict monitoring of urine output, GCS, watching for seizures and features of upper gastrointestinal bleed. From the second day of stoppage of the drug, repeat laboratory tests showed gradual improvement in liver functions (Figure 1 and Figure 2) paralleling clinical improvement.

Although restarting the patient with the same drug and aided with liver biopsy would be more diagnostic, in our case, the patient's hepatic function rapidly normalized following stoppage of only levetiracetam from our prescribed drug lists. Therefore, we sufficiently concluded that levetiracetam caused the hepatotoxicity. Though rare, we would like to stress upon the importance of keeping this rare but life-threatening complications of levetiracetam in mind, as it can have profound effect on the timely and corrective management of the patient. There was no episode of recurrence of jaundice seen in the patient within the ensuing 3 weeks.

Discussion

Seizures complicate up to 20% of cases with spontaneous intracerebral hemorrhage⁷. There is no high level of evidence favoring the use of a specific AED⁷. Levetiracetam is one of the most commonly used AED in current clinical practice due to its relatively good drug safety profile, and most adverse effects mentioned are usually mild to moderate in intensity⁸. Levetiracetam does not inhibit or induce hepatic enzymes and most of it is eliminated unchanged by the kidneys. Thus, because it is minimally protein bound and lacks metabolism by the liver, the risk of hepatotoxicity is low. Thus, levetiracetam has a wide safety margin⁸.

However, while reviewing literature, we found a few case reports citing hepatotoxicity with levetiracetam usage⁴⁻⁶. As per the current recommendations by the Council for International Organization of Medical Sciences (CIOMS) for diagnosing drug induced liver injury, our case was of hepatocellular variant⁹. However, there is no consensus or diagnostic modality in correctly determining the implicated drugs, and thereby this has to be relied solely on the basis of empirical decision as to discontinue or modify drugs during such a scenario⁹.

Tan *et al.* reported incidence of fulminant liver failure owing to levetiracetam⁴. Syed and Adams also reported a case of liver failure following prophylactic levetiracetam usage in a patient with head injury⁵. Sethi *et al.* reported a post-traumatic head

Figure 1. Changes in liver enzymes subsequent to stoppage of levetiracetam over a period of days (x-axis).

Figure 2. Changes in the bilirubin (mg/dl) subsequent to stoppage of levetiracetam over a period of days (x-axis).

injury patient who developed asymptomatic elevation of hepatic enzymes following levetiracetam usage⁶.

Conclusion

Though safe and free of major side effects when comparing to older AED, it is however prudent to note that there are reports of liver injury following levetiracetam, ranging from asymptomatic elevation of transaminases to fulminant hepatic failure. Though routine liver or renal function monitoring may not be

needed, it is advisable to keep the patient informed of such possible side effects with the use of newer AED like levetiracetam.

Consent

Since the patient was not fully conscious and alert enough to understand the concept of signing consent (since he was in a rehabilitation phase following intracranial hemorrhage), written informed consent for the publication of the relevant clinical and radiological data was obtained from the patient's wife.

Data availability

All data underlying the results are available as part of the article and no additional source data are required.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- Mehta A, Zusman BE, Choxi R, *et al.*: **Seizures After Intracerebral Hemorrhage: Incidence, Risk Factors, and Impact on Mortality and Morbidity.** *World Neurosurg.* 2018; **112**: e385–e392.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Vidaurre J, Gedela S, Yarosz S: **Antiepileptic Drugs and Liver Disease.** *Pediatr Neurol.* 2017; **77**: 23–36.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Vidaurre J, Gedela S, *et al.*: **Topical Review-Antiepileptic Drugs and Liver Disease; Division of Pediatric Neurology, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio.**
- Tan TC, de Boer BW, Mitchell A, *et al.*: **Levetiracetam as a possible cause of fulminant liver failure.** *Neurology.* 2008; **71**(9): 685–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Syed AA, Adams CD: **Acute liver failure following levetiracetam therapy for seizure prophylaxis in traumatic brain injury.** *Case Rep Clin Med.* 2012; **1**(2): 41–4.
[Publisher Full Text](#)
- Sethi NK, Sethi PK, Torgovnick J, *et al.*: **Asymptomatic elevation of liver enzymes due to levetiracetam: a case report.** *Drug Metabol Drug Interact.* 2013; **28**(2): 123–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Arboix A, Garcia-Eroles L, Massons JB, *et al.*: **Predictive factors of early seizures after acute cerebrovascular disease.** *Stroke.* 1997; **28**(8): 1590–1594.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Harden C: **Safety profile of levetiracetam.** *Epilepsia.* 2001; **42** Suppl 4(s4): 36–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Danan G, Benichou C: **Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.** *J Clin Epidemiol.* 1993; **46**(11): 1323–1330.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 01 April 2019

<https://doi.org/10.5256/f1000research.19906.r46049>

© 2019 Shankar P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pathiyil Ravi Shankar

Department of Pharmacology, Health City University, Gros Islet, Saint Lucia

My specific comments to further strengthen the manuscript are shown below.

Abstract Section:

Case presentation subsection: Line 5, the word 'inciting' can be replaced by a more suitable word.

Conclusions subsection: Line 1, 'adverse effect' may be a more appropriate term than 'side effect'.

Key words: More key words can be added. Key words can be arranged alphabetically.

Page 2, column 1, Case report section, paragraph 1, Line 9: Do the authors mean emergency instead of emergent?

The quality of written English is generally good but corrections may be required in a few places. I agree with the other reviewer that the authors can carry out a causality, severity and preventability assessment of the adverse drug reaction.

Also, information about the medicines used preoperatively and during anesthesia will be helpful as suggested by the other reviewer.

Does the institution have a functioning pharmacovigilance center? Was the adverse drug reaction reported to the center?

Is the background of the case's history and progression described in sufficient detail?

Yes

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?

Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Yes

Is the case presented with sufficient detail to be useful for other practitioners?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pharmacovigilance, pharmacoepidemiology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 25 March 2019

<https://doi.org/10.5256/f1000research.19906.r46050>

© 2019 Palaian S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Subish Palaian

Department of Pharmacy Practice, College of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates

General comments: It is a timely report representing an important area of clinical practice and hence deserves indexing.

Specific comments:

- Authors must mention these points in the case report section:

Whether this patient had a history of liver problems in the recent past?

Any previous history of allergy to any other drugs?

Was there use of potentially hepatotoxic general anaesthetic agent?

Is he taking any other medications at the time of admission?

Is the patient an alcoholic?

Any other predisposing factors that could have potentially caused/augmented this adverse drug reaction?

- Causality assessment: It will be nice for the authors to perform a 'Causality assessment' and grade the Causal relationship between the drug and the event. I recommend using Naranjo scale.
- Severity assessment: The severity assessment gives an opportunity for the authors to categorize the adverse drug reaction based on its severity. Authors could use the 'Hartwig Scale' for this purpose.
- In 'Case report' Section, ...remote village in Biratnagar, Nepal. (add 'Nepal')
- 'Discussion section' should emphasize on the management pattern patient (in relation to the adverse drug reactions) highlighting any supportive treatment provided in this patient. This could be even mentioned partly under the 'Case report' section.

Is the background of the case's history and progression described in sufficient detail?

Partly

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?

Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Yes

Is the case presented with sufficient detail to be useful for other practitioners?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pharmacovigilance

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research